Profile data is unavailable for this security.
About the company
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
- Revenue in USD (TTM)40.56m
- Net income in USD-194.65m
- Incorporated2017
- Employees168.00
- LocationZentalis Pharmaceuticals Inc10275 Science Center Drive, Suite 200SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 263-4333
- Fax+1 (302) 655-5049
- Websitehttps://www.zentalis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Climb Bio Inc | 0.00 | -64.20m | 272.26m | 9.00 | -- | 1.22 | -- | -- | -2.15 | -2.15 | 0.00 | 3.33 | 0.00 | -- | -- | 0.00 | -37.51 | -- | -38.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| Editas Medicine Inc | 61.76m | -210.57m | 272.41m | 265.00 | -- | 1.55 | -- | 4.41 | -2.56 | -2.56 | 0.752 | 2.13 | 0.1484 | -- | 48.48 | 233,049.10 | -50.61 | -29.85 | -60.06 | -33.19 | -- | -- | -340.96 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
| MacroGenics Inc | 141.33m | -97.62m | 275.53m | 339.00 | -- | 2.29 | -- | 1.95 | -1.57 | -1.57 | 2.26 | 1.91 | 0.4676 | 3.24 | 8.30 | 416,899.70 | -32.30 | -37.76 | -39.53 | -45.53 | 95.07 | -- | -69.07 | -133.96 | 3.69 | -93.94 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
| Abeona Therapeutics Inc | 0.00 | -52.60m | 278.51m | 84.00 | -- | 3.66 | -- | -- | -2.13 | -2.13 | 0.00 | 1.76 | 0.00 | -- | -- | 0.00 | -56.09 | -53.22 | -65.23 | -65.81 | -- | -- | -- | -1,894.25 | -- | -- | 0.2004 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
| Heron Therapeutics Inc | 136.36m | -48.13m | 279.07m | 126.00 | -- | -- | -- | 2.05 | -0.3249 | -0.3249 | 0.9094 | -0.2503 | 0.6503 | 1.08 | 1.81 | 1,082,230.00 | -22.95 | -53.55 | -38.15 | -71.24 | 65.49 | 52.52 | -35.29 | -170.12 | 1.85 | -- | 1.34 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
| Kodiak Sciences Inc | 0.00 | -197.68m | 280.96m | 111.00 | -- | 1.31 | -- | -- | -3.77 | -3.77 | 0.00 | 4.08 | 0.00 | -- | -- | 0.00 | -39.89 | -31.73 | -44.14 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
| Pyxis Oncology Inc | 16.15m | -59.20m | 281.66m | 51.00 | -- | 1.64 | -- | 17.44 | -1.26 | -1.26 | 0.3269 | 2.88 | 0.0842 | -- | -- | 322,920.00 | -30.87 | -- | -33.12 | -- | 97.06 | -- | -366.67 | -- | -- | -- | 0.0008 | -- | -- | -- | 38.87 | -- | -- | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -88.51m | 282.04m | 20.00 | -- | -- | -- | -- | -2.52 | -2.52 | 0.00 | -0.2208 | 0.00 | -- | -- | 0.00 | -77.89 | -38.44 | -81.83 | -39.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 54.16 | -- | -- | -- |
| aTyr Pharma Inc | 235.00k | -63.82m | 282.05m | 56.00 | -- | 3.90 | -- | 1,200.20 | -0.9365 | -0.9365 | 0.0034 | 0.8617 | 0.0022 | -- | 0.12 | 4,196.43 | -58.90 | -45.45 | -67.15 | -52.74 | -- | -- | -27,155.32 | -784.19 | -- | -- | 0.0233 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
| Atea Pharmaceuticals Inc | 0.00 | -174.01m | 283.66m | 75.00 | -- | 0.6189 | -- | -- | -2.07 | -2.07 | 0.00 | 5.43 | 0.00 | -- | -- | 0.00 | -31.67 | -5.90 | -32.99 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
| Zentalis Pharmaceuticals Inc | 40.56m | -194.65m | 286.57m | 168.00 | -- | 0.749 | -- | 7.07 | -2.75 | -2.75 | 0.5719 | 5.38 | 0.0729 | -- | 15.94 | 241,428.60 | -34.99 | -47.40 | -39.16 | -54.18 | -- | -- | -480.07 | -- | -- | -- | 0.00 | -- | -- | -- | -23.39 | -- | 20.76 | -- |
| ADC Therapeutics SA | 70.72m | -212.15m | 288.14m | 273.00 | -- | -- | -- | 4.07 | -2.40 | -2.40 | 0.7742 | -1.78 | 0.1733 | 0.2987 | 3.13 | 259,036.60 | -51.13 | -48.41 | -62.27 | -55.63 | 91.81 | -- | -295.00 | -308.62 | 4.68 | -3.92 | 1.65 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
| Biomea Fusion Inc | 0.00 | -144.01m | 291.00m | 107.00 | -- | 3.83 | -- | -- | -4.00 | -4.00 | 0.00 | 2.10 | 0.00 | -- | -- | 0.00 | -85.85 | -- | -98.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
| Fate Therapeutics Inc | 12.32m | -175.72m | 291.53m | 181.00 | -- | 0.7342 | -- | 23.67 | -1.71 | -1.71 | 0.1185 | 3.49 | 0.0221 | -- | 6.35 | 68,049.73 | -31.56 | -31.82 | -33.99 | -36.05 | -- | -- | -1,426.67 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
| Zura Bio Ltd | 0.00 | -42.62m | 301.01m | 14.00 | -- | 2.01 | -- | -- | -0.5807 | -0.5807 | 0.00 | 2.34 | 0.00 | -- | -- | 0.00 | -32.18 | -- | -43.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2,050.99 | -- | -- | -- |
Data as of Nov 12 2024. Currency figures normalised to Zentalis Pharmaceuticals Inc's reporting currency: US Dollar USD
67.38%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Matrix Capital Management Co. LPas of 30 Jun 2024 | 13.96m | 19.63% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 7.28m | 10.24% |
| Eventide Asset Management LLCas of 31 Oct 2024 | 7.09m | 9.97% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 4.61m | 6.49% |
| Citadel Advisors LLCas of 30 Jun 2024 | 4.33m | 6.09% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 4.32m | 6.07% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 1.91m | 2.68% |
| Woodline Partners LPas of 30 Jun 2024 | 1.52m | 2.13% |
| PRIMECAP Management Co.as of 30 Sep 2024 | 1.50m | 2.11% |
| FIAM LLCas of 30 Jun 2024 | 1.40m | 1.96% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
